Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex

Journal of Investigative Dermatology

Volumn 131, Issue 10, 2011, Pages 2079-2086

  Atkinson, Sarah D ^a,b   McGilligan, Victoria E ^a,b   Liao, Haihui ^a   Szeverenyi, Ildiko ^c   Smith, Frances J D ^a   Moore, C B Tara ^a,b   McLean, W H Irwin ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; LUCIFERASE; SMALL INTERFERING RNA;

ARTICLE; CELL AGGREGATION; CONTROLLED STUDY; CYTOSKELETON; DRUG SPECIFICITY; DRUG SYNTHESIS; EPIDERMOLYSIS BULLOSA SIMPLEX; GENE SILENCING; GENETIC SCREENING; HUMAN; HUMAN CELL; MISSENSE MUTATION; MUTANT; PRIORITY JOURNAL; REPORTER GENE; RNA INTERFERENCE; WILD TYPE;

EID: 80052865748     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.169     Document Type: Article

References (33)

1. Anton-Lamprecht I, Schnyder UW (1982) Epidermolysis bullosa herpetiformis Dowling-Meara. Report of a case and pathomorphogenesis. Dermato-logica 164:221-35 (Pubitemid 12155232)
2. Atkinson S, McGilligan VE, Liao H et al. (2010) Allele-specific siRNA therapy for epidermolysis bullosa simplex. Br J Dermatol 162:926
3. Bonifas JM, Rothman AL, Epstein EH (1991) Epidermolysis bullosa simplex: evidence in two families for keratin gene abnormalities. Science 254:1202-5 (Pubitemid 21917453)
4. Bumcrot D, Manoharan M, Koteliansky V et al. (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2:711-9 (Pubitemid 44764213)
5. Cao T, Longley MA, Wang X-J et al. (2001) An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy. J Cell Biol 152:651-6 (Pubitemid 34280246)
6. Caplen NJ, Parrish S, Imani F et al. (2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 98:9742-7 (Pubitemid 32769374)
7. Coulombe PA, Hutton ME, Letai A et al. (1991) Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analysis. Cell 66:1301-11 (Pubitemid 121001418)
8. Dykxhoorn DM, Lieberman J (2006) Knocking down disease with siRNAs. Cell 126:231-5 (Pubitemid 44092975)
9. Dykxhoorn DM, Schlehuber LD, London IM et al. (2006) Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci USA 103:5953-8
10. Elbashir SM, Harborth J, Lendeckel W et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-8 (Pubitemid 32494397)
11. Fine JD, Eady RA, Bauer EA et al. (2008) The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 58:931-50
12. Fritsch A, Spassov S, Elfert S et al. (2009) Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII. J Biol Chem 284:30248-56
13. Hickerson RP, Smith FJD, McLean WHI et al. (2006) SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann N Y Acad Sci 1082:56-61 (Pubitemid 44955450)
14. Hickerson RP, Smith FJD, Reeves RE et al. (2008) Single-nucleotide- specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 128:594-605 (Pubitemid 351252662)
15. Horn HM, Priestly GC, Eady RAJ et al. (1997) The prevalence of epidermolysis bullosa in Scotland. Br J Dermatol 136:560-4 (Pubitemid 27160331)
16. Humphries MM, Mansergh FC, Kiang AS et al. (1996) Three keratin gene mutations account for the majority of dominant simplex epidermolysis bullosa cases within the population of Ireland. Hum Mutat 8:57-63 (Pubitemid 26238970)
17. Irvine AD, McLean WHI (1999) Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br J Dermatol 140:815-28 (Pubitemid 29238452)
18. Ishida-Yamamoto A, McGrath JA, Chapman SJ et al. (1991) Epidermolysis bullosa simplex (Dowling-Meara type) is a genetic disease characterized by an abnormal keratin filament network involving keratins K5 and K14. J Invest Dermatol 97:959-68
19. Kashani-Sabet M (2002) Ribozyme therapeutics. J Investig Dermatol Symp Proc 7:76-8 (Pubitemid 36151098)
20. Kaspar RL (2005) Challenges in developing therapies for rare diseases including pachyonychia congenita. J Investig Dermatol Symp Proc 10:62-6
21. Kaspar RL, McLean WH, Schwartz ME (2009) Achieving successful delivery of nucleic acids to skin: 6th Annual Meeting of the International Pachyonychia Congenita Consortium. J Invest Dermatol 129:2085-7
22. Lane EB, McLean WHI (2008) Broken bricks and cracked mortar: epidermal diseases resulting from genetic abnormalities. Drug Discov Today 5:e93-e101
23. Lane EB, Rugg EL, Navsaria H et al. (1992) A mutation in the conserved helix termination peptide of keratin 5 in hereditary skin blistering. Nature 356:244-6
24. Leachman SA, Hickerson RP, Hull PR et al. (2008) Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51:151-7
25. Leachman SA, Hickerson RP, Schwartz ME et al. (2010) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 18:442-6
26. McGilligan VE, Atkinson S, Liao H et al. (2010) Mutation-specific siRNA therapy for epidermolysis bullosa simplex. J Invest Dermatol 130:S91
27. Pfendner E, Uitto J, Fine JD (2001) Epidermolysis bullosa carrier frequencies in the US population. J Invest Dermatol 116:483-4 (Pubitemid 32202923)
28. Rugg EL, Horn HM, Smith FJ et al. (2007) Epidermolysis bullosa simplex in Scotland caused by a spectrum of keratin mutations. J Invest Dermatol 127:574-80
29. Shemanko CS, Horn HM, Keohane SG et al. (2000) Laryngeal involvement in the Dowling-Meara variant of epidermolysis bullosa simplex with keratin mutations of severely disruptive potential. Br J Dermatol 142:315-20 (Pubitemid 30117704)
30. Smith FJD, Porter RM, Corden LD et al. (2002) Cloning of human, murine, and marsupial keratin 7 and a survey of K7 expression in the mouse. Biochem Biophys Res Commun 297:818-27 (Pubitemid 35237990)
31. Szeverenyi I, Cassidy AJ, Chung CW et al. (2008) The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat 29:351-60 (Pubitemid 351364936)
32. Wally V, Brunner M, Lettner T et al. (2010) K14 mRNA reprogramming for dominant epidermolysis bullosa simplex. Hum Mol Genet 19:4715-25
33. Yokota T, Miyagishi M, Hino T et al. (2004) siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme. Biochem Biophys Res Commun 314:283-91 (Pubitemid 38058398)